CLTB: A Protein with Potential as A Drug Target Or Biomarker (G1212)

Target Name: CLTB

NCBI ID: G1212

CLTB

CLTB: A Protein with Potential as A Drug Target Or Biomarker

CLTB, or Creatine kinase light chain kinase B, is a protein that is expressed in various tissues throughout the body, including muscle, heart, brain, and testses. It is a key enzyme in the muscle cell metabolism, and is involved in the process of muscle growth and repair.

CLTB has also been shown to play a key role in the development and progression of several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its role in these diseases has led to a growing interest in using CLTB as a drug target or biomarker.

One of the main advantages of CLTB as a drug target is its ability to be modified and exploited for therapeutic purposes. Researchers have identified several potential CLTB-targeted small molecules that have been shown to promote muscle growth and repair, and to have anti-cancer and anti-neurodegenerative effects. These molecules can be administered to animals or humans to treat a range of diseases, including muscle-related conditions, cancer, and neurodegenerative diseases.

Another advantage of CLTB is its expression in a variety of tissues, which makes it an attractive target for drugs that are designed to have a broad therapeutic effect. For example, studies have shown that CLTB is expressed in muscle, brain, and heart tissue, which makes it an potential target for drugs that can affect any of these tissues. This can be important for developing drugs that have a more comprehensive impact on disease, rather than targeting a specific tissue or molecule.

CLTB has also been shown to be involved in several important cellular processes that are involved in disease development and progression. For example, CLTB is involved in the regulation of cell division, which is critical for the growth and development of tissues. It is also involved in the regulation of muscle growth and repair, which is important for maintaining muscle mass and function.

In addition to its potential as a drug target, CLTB is also a potential biomarker for several diseases. Its expression has been shown to be elevated in a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This suggests that CLTB may be a useful biomarker for these diseases, and that its levels can be used to monitor disease progression and the effectiveness of treatments.

Overall, CLTB is a protein that has broad potential as a drug target or biomarker. Its role in muscle cell metabolism and its expression in a variety of tissues make it an attractive target for small molecules that have been shown to promote muscle growth and repair, as well as for diseases that involve these processes, such as cancer and neurodegenerative diseases. Further research is needed to fully understand the role of CLTB in disease and to develop effective treatments.

Protein Name: Clathrin Light Chain B

Functions: Clathrin is the major protein of the polyhedral coat of coated pits and vesicles

The "CLTB Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CLTB comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets